Podcasts about jointly

Foreign minister Winston Peters is chalking up news of a new port in the Cook Islands as a major win for Pacific regionalism. Peters is in Palau for the Pacific Islands Forum leaders meeting and earlier today announced NZ and the US will be jointly funding a major port upgrade in the most northern island in the Cooks group. Teuila Fuatai spoke to Melissa Chan-Green from Koror.

In children with septic shock, does the choice between balanced crystalloids and 0.9% saline actually matter? This episode reviews the composition and physiologic differences between commonly used crystalloids, summarizes the 2026 PRoMPT BOLUS trial, and discusses how its findings fit with the updated Surviving Sepsis Campaign pediatric guidelines. We also consider the trial's limitations and what the results mean for fluid selection at the bedside. Learning Objectives By the end of this episode, listeners should be able to: Compare the composition and physiologic effects of 0.9% saline and balanced crystalloids used for pediatric fluid resuscitation. Summarize the design and major findings of the PRoMPT BOLUS trial. Describe important limitations of PRoMPT BOLUS when applying its results to children with septic shock. Apply current evidence and 2026 Surviving Sepsis Campaign recommendations when selecting crystalloid fluids for pediatric septic shock. References Weiss SL, Peters MJ, Oczkowski SJW, et al. Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026. Pediatr Crit Care Med. 2026. Published April 1, 2026. Jointly issued by the Society of Critical Care Medicine and Infectious Diseases Society of America. Recommendation 24 suggests balanced/buffered crystalloids over 0.9% saline for children with septic shock requiring fluid boluses (conditional recommendation, very low certainty), while recognizing 0.9% saline as a suitable alternative and preferred in selected situations such as hyponatremia or concern for increased intracranial pressure. Balamuth F, Weiss SL, Long E, et al. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock. N Engl J Med. 2026. Published April 24, 2026. PRoMPT BOLUS was a large pragmatic randomized trial comparing balanced crystalloids with 0.9% saline in children treated for suspected septic shock and found no reduction in major adverse kidney events within 30 days with balanced fluids. Transcript This transcript was generated using Descript and subsequently reviewed and lightly edited for spelling, grammar, and clarity. Minor inaccuracies may remain, and the audio recording should be considered the definitive version of this content. Welcome to PEM Currents: The Pediatric Emergency Medicine Podcast. As always, I'm your host, Brad Sobolewski, and today we're gonna talk about which fluid we should use when managing a septic pediatric patient. So when we resuscitate a child with septic shock, the major decision is usually not whether to give crystalloid, but which crystalloid to give. And for a long time, there's been a gradual shift towards balanced fluids such as Lactated Ringer's or Plasma-Lyte, largely because they are more physiologic and produce less hyperchloremia than normal saline. The question's always been whether those biochemical differences actually translate into better clinical outcomes. That is the question that a study called PRoMPT BOLUS was designed to answer. So before getting into the trial, it's worth briefly reviewing what these fluids actually contain. So normal saline is 0.9% sodium chloride. It contains one hundred and fifty-four milliequivalents per liter of sodium and a hundred and fifty-four milliequivalents per liter of chloride. The chloride concentration is substantially higher than plasma. Balanced crystalloids contain less chloride and have some other electrolytes and a buffer. Lactated Ringer's contains approximately a hundred and thirty milliequivalents per liter of sodium, one hundred and nine of chloride, four of potassium, a small amount of calcium, and lactate as a buffer. Plasma-Lyte contains approximately one hundred and forty of sodium, ninety-eight of chloride, five of potassium, magnesium, and acetate and gluconate as buffers. The concern with normal saline is that the large chloride loads can produce hyperchloremic metabolic acidosis. There's also been concern about adverse effects on renal blood flow and kidney function. Balanced fluids are designed to more closely approximate plasma composition, so the hypothesis has been that they might reduce kidney injury. That hypothesis has been supported by physiologic data and by some adult studies, although pediatric evidence before PRoMPT BOLUS was limited and inconsistent. The 2026 Surviving Sepsis Campaign Pediatric Guidelines recommend crystalloids over albumin for initial resuscitation and conditionally suggest balanced or buffered crystalloids over 0.9% saline in children with septic shock who require fluid boluses. Importantly, that recommendation is based on very low-certainty evidence. Balanced options again include Lactated Ringer's, Hartmann's solution, or Plasma-Lyte. If balanced fluids are not readily available, saline remains an acceptable alternative. Saline may also be preferable in some specific situations like significant hyponatremia or concern for increased intracranial pressure. For children in resource-abundant settings, the general approach is still ten to twenty mLs per kilo per bolus with reassessment after each bolus, potentially up to forty to sixty mLs per kilo in the first hour if perfusion remains abnormal and there are no signs of fluid overload. Now, PRoMPT BOLUS, the full name of which is the Pragmatic Pediatric Trial of Balanced versus Normal Saline Fluid in Sepsis, was an international randomized pragmatic trial designed to specifically compare the two fluid strategies in children with suspected septic shock. The final trial enrolled nine thousand and forty-one children from two months to younger than eighteen years across forty-seven emergency departments in five countries. Children were randomized to predominantly balanced crystalloid or predominantly 0.9% saline, and the assigned fluid strategy was used for bolus and maintenance crystalloid during the initial treatment period. The balanced fluid arm was not a single product. Depending on the site, children could get Lactated Ringer's, Hartmann's solution, or Plasma-Lyte. That's important when interpreting the study. PRoMPT BOLUS was really testing a strategy of predominantly balanced crystalloid versus a strategy of predominantly saline use rather than comparing LR versus saline alone, though LR was the most commonly used one. The primary outcome was something called MAKE30, M-A-K-E thirty, or major adverse kidney events within thirty days. This was a composite outcome that included death, new renal replacement therapy, or persistent kidney dysfunction. That choice of outcome is useful because the biologic rationale for balanced fluids has always centered largely on kidney protection. The investigators were therefore asking whether the lower chloride exposure associated with balanced fluids translated into clinically meaningful renal benefit. So what was the result? Well, the spoiler is that the answer was no. So MAKE30 occurred in three point four percent of children receiving balanced fluids and three percent receiving saline. The relative risk was one point one with a ninety-five percent confidence interval from point eight eight to one point four. There were also no significant differences in death, new renal replacement therapy, persistent kidney dysfunction, or hospital-free days. In practical terms, balanced crystalloids did not improve the major patient-centered outcomes the trial was designed to measure. There were clear biochemical differences between the groups. Hyperchloremia occurred in thirty-one point four percent of children receiving balanced fluids compared with forty-nine percent with saline. Hypernatremia was also less common with balanced fluids, one point eight versus three point one percent. Hyperlactatemia was slightly more common in the balanced fluid group, nineteen point eight compared with sixteen point seven percent. So the fluids behaved differently in the ways that you would expect physiologically. Balanced crystalloids clearly reduced hyperchloremia, but that difference did not translate into fewer major kidney events, less dialysis, shorter hospitalization, or lower mortality. There are several limitations to this study worth keeping in mind. The first is that this was a broad emergency department population with suspected septic shock, not a study limited to children with the most severe forms of shock. Only a minority of patients required vasoactive medications, and overall mortality was low. The results are therefore most applicable to the typical child with suspected septic shock receiving early ED resuscitation. They do not completely answer whether fluid composition might matter more in a smaller subgroup of children receiving very large fluid volumes or prolonged resuscitation. The second limitation is that the event rate for MAKE30 was lower than expected. When the trial was designed, investigators anticipated an event rate of about six percent in the saline group. The observed rate was closer to three percent. That means there were fewer outcome events than anticipated, which reduced the ability to detect a very small treatment effect. So the trial makes a large benefit from balanced fluids unlikely, but it can't exclude a small or subtle difference. A third limitation is that the balanced fluid group included several different solutions. Lactated Ringer's, Plasma-Lyte, and Hartmann's are all considered under the umbrella of balanced crystalloids, but they're not chemically identical. The study therefore supports the broader conclusion that a balanced fluid strategy is not superior to saline for most children in this setting, rather than providing equivalence between any single specific balanced solution and saline, even though Lactated Ringer's is used far and away most often. The trial was also intentionally pragmatic, which means that there was some crossover between fluid types. Adherence was defined as receiving at least seventy-five percent of crystalloid as the assigned fluid rather than requiring exclusive use of one fluid. That could reduce the ability to detect a small treatment effect, but it also makes the study more reflective of real clinical practice. The investigators themselves described the trial as a comparison of predominant rather than exclusive use of balanced crystalloids versus saline. Finally, the trial was open label, so clinicians knew which fluid the child was receiving. That introduces the possibility of treatment bias, though the primary outcome relied on relatively objective measures. A substantial proportion of children also did not have a measured baseline creatinine, so baseline kidney function sometimes had to be imputed using age- and sex-based values. That's worth remembering because persistent kidney dysfunction was part of the primary composite outcome. Taken together, I think PRoMPT BOLUS makes the bedside decision simpler. Balanced fluids remain a completely reasonable and defensible choice. They cause less hyperchloremia, and there's no reason to abandon them if they're already part of your usual resuscitation fluid strategy or your order sets. At the same time, the largest pediatric randomized trial now shows no improvement in major kidney or mortality outcomes compared with normal saline. So if you use saline at your local hospital, that's okay too. The 2026 Surviving Sepsis Campaign still conditionally favors balanced crystalloids, but that recommendation is based on very low-certainty evidence. So PRoMPT BOLUS adds important randomized data suggesting that for most children with septic shock, either crystalloid strategy is reasonable. The practical takeaway is that the choice of crystalloid is probably less important than getting the resuscitation itself right. Give 10 to 20 mLs per kilo when a fluid bolus is indicated, reassess frequently, watch for improvement in perfusion and for signs of fluid overload, and move to vasoactive support when fluid alone is not correcting the shock. Balanced crystalloids will produce less hyperchloremia. Normal saline will produce more. In PRoMPT BOLUS, that biochemical difference did not translate into a difference in kidney injury, dialysis, or mortality. For most children with septic shock, balanced fluids are fine, normal saline is fine, and timely, thoughtful resuscitation matters much more than which bag is hanging. I hope you found this episode on fluids for sepsis in children helpful and that you'll be able to take this knowledge back to the bedside the next time you work in the emergency department. If you've got other topics you want me to cover, especially as they relate to practice-changing research in pediatrics, like the PRoMPT BOLUS trial from the Pediatric Emergency Care Applied Research Network, PECARN as we call it, let me know. Send it my way. If you have time to leave a review on your favorite podcast site, please do so. It helps other people find the show, and definitely share this with your colleagues. I think this study and perhaps this podcast episode could be a great combo for an upcoming journal club. For PEM Currents, the Pediatric Emergency Medicine Podcast, this has been Brad Sobolewski. See you next time.  

Shanghai is expanding overseas access to computing power and foundational artificial intelligence models to boost the city's trade in services, with a new plan setting a goal of increasing the sector's scale to more than $300 billion by 2030.上海正面向海外开放算力以及基础人工智能模型资源，以此拉动本市服务贸易；一份全新规划定下目标：2030年前服务贸易规模突破3000亿美元。Experts said that the move would help make AI a new growth driver and strengthen the city's role as a global trade in services hub.专家表示，该举措能够促使人工智能成为全新增长引擎，并巩固上海全球服务贸易枢纽的地位。On Monday, a plan to build Shanghai into a national demonstration zone for service trade innovation and development was unveiled.本周一，上海建设国家服务贸易创新发展示范区的规划正式对外公布。Jointly released by seven departments, including the Shanghai Municipal Commission of Commerce, the plan sets a goal of increasing the city's service trade volume to $270 billion by 2027 and surpassing $300 billion by 2030.该规划由上海市商务委员会等七个部门联合印发；计划提出，2027年上海服务贸易总额达到2700亿美元，2030年突破3000亿美元。The plan calls for the development of service trade related to the AI industry, attracting global companies and institutions to establish AI R&D centers, opensource platforms and joint laboratories in Shanghai, and building an open innovation ecosystem.规划提出发展人工智能产业相关服务贸易，吸引海内外企业与机构在沪设立人工智能研发中心、开源平台以及联合实验室，搭建开放式创新生态体系。Coordinated development协同发展Zhong Junhao, secretarygeneral of the Shanghai AI Industry Association, said that for the first time, the plan incorporates the coordinated development of the AI industry into the broader framework of a city's service trade development, marking the use of computing power as a new growth driver for the sector.上海市人工智能行业协会秘书长钟俊浩称，这份规划首次将人工智能产业协同发展纳入全市服务贸易发展的整体框架，标志着算力正式成为服务贸易全新增长动力。"Encouraging companies and institutions to establish AI R&D centers, opensource platforms and joint laboratories in Shanghai is essentially an openingup of both the import and international cooperation sides of trade in services," Zhong said.钟俊浩表示：“鼓励各类企业、机构落地上海搭建人工智能研发中心、开源平台、联合实验室，本质上是服务贸易在进口领域和国际合作层面的双向对外开放。”By bringing talent, code, research facilities and opensource communities to Shanghai, he said the city can create a platform connecting international institutions, multinational R&D units and local innovation communities within the same network.他谈到，通过集聚人才、程序代码、科研设施与开源社群，上海可打造一体化平台，连通国际机构、跨国企业研发部门以及本土创新社群。On July 16, 29 countries signed an agreement in Shanghai to establish the World Artificial Intelligence Cooperation Organization. Headquartered in Shanghai, the organization is officially positioned as an independent intergovernmental international body focusing on capacity building, alignment of rules and standards, application cooperation and global AI governance.7月16日，29个国家于上海签署协议，成立世界人工智能合作组织。该组织总部落户上海，定位为独立的政府间国际机构，主攻能力建设、规则标准对接、应用合作以及全球人工智能治理。The trade in services demonstration zone plan includes measures to accelerate headquarters development and explore governance, adding institutional support for Shanghai's international AI cooperation, Zhong said.钟俊浩介绍，这份服务贸易示范区方案含有加快总部经济建设、探索新型治理模式的多项举措，为上海开展人工智能国际合作提供制度保障。Complete ecosystem完备产业生态Addressing a news conference in July, Chen Jie, vicemayor of Shanghai, said, "Shanghai has now built a complete development ecosystem that integrates independent innovation, applicationdriven growth, open collaboration, ecological synergy and security governance."上海市副市长陈杰于7月的新闻发布会上发言：“上海现已建成集自主创新、应用牵引增长、开放协作、生态协同、安全治理于一体的完整发展生态。”According to him, Shanghai's 394 AI enterprises above the designated size, each with an annual revenue of at least 20 million yuan ($2.96 million), saw their combined industry scale exceed 637 billion yuan in 2025, a yearonyear increase of 39.5 percent, making AI a new growth driver for the city's economy.据其介绍，上海现有394家规模以上人工智能企业（年营收不低于2000万元，折合296万美元）；2025年产业总规模突破6370亿元，同比上涨39.5%，人工智能已然成为上海经济全新增长引擎。The plan outlines 27 key tasks across six areas, covering industrial and supply chain upgrading, innovation in new business models, stronger business competitiveness, more efficient supply, higherlevel openingup, and mechanisms to support both domestic and international development.该规划从六大方向部署27项重点任务，涵盖产业链供应链升级、新业态模式创新、增强企业竞争力、优化供给效能、高水平对外开放、搭建兼顾国内外发展的保障机制。Qi Xiaozhai, vicechairman of the Commerce Economy Association of China, said: "In the past, we placed greater emphasis on trade in goods than on trade in services, especially service exports. However, in recent years, service trade has grown much faster than goods trade. Last year, the value of service trade reached 8.08 trillion yuan, up 7.4 percent yearonyear, 3.6 percentage points higher than the growth rate of goods trade."中国商业经济学会副会长齐晓斋表示：“过去我国重货物贸易、轻服务贸易，尤其忽视服务出口。但近些年服务贸易增速远超货物贸易；去年我国服务贸易总额达8.08万亿元，同比增长7.4%，增速比货物贸易高出3.6个百分点。”"Domestic consumption of services, including catering, entertainment and leisure, has also grown faster than the consumption of goods. Against this backdrop, China has developed new advantages in service trade, particularly in emerging digital technologies such as AI, big data, cloud computing and blockchain," Qi added.齐晓斋补充道：“餐饮、文娱休闲等国内服务消费增速同样高于商品消费。在此背景之下，我国服务贸易培育出新优势，尤其在人工智能、大数据、云计算、区块链等新兴数字技术领域。”By 2035, China aims to establish around 35 demonstration zones with leading service trade scale, concentrated highend resources, strong innovation capabilities and significant regional influence, he said.他称，我国计划至2035年建成大约35处服务贸易示范区；示范区需要做到贸易规模领先、高端资源集聚、创新能力出众、区域辐射影响力强劲。The country will foster a number of internationally competitive service export enterprises and key service industry clusters, while forming a development pattern in which service trade, investment, consumption and industries are interconnected and mutually reinforcing, he added.他还提到，国家将培育一批具备国际竞争力的服务出口企业以及重点服务业产业集群，促成服务贸易、投资、消费、实体经济互联互通、相辅相成的发展格局。foundational /faʊnˈdeɪʃənl/基础的；根基性的intergovernmental /ˌɪntəɡʌvənˈmentl/政府间的cluster /ˈklʌstə(r)/产业集群，集聚片区

Former Investigating Directorate Against Corruption (IDAC) Head Advocate Andrea Johnson has conceded before the Madlanga Commission that suspended National Police Commissioner General Fannie Masemola should not have been joined with accused persons facing fraud and corruption charges, Masemola faces charges under the Public Finance Management Act (PFMA) tied to the alleged irregular awarding of an R228 million SAPS tender to Medicare 24. Johnson agreed that Masemola, who faces only charges under the Public Finance Management Act (PFMA), could be prejudiced by being tried alongside those accused of serious corruption offences. However, she rejected suggestions that prosecutors deliberately sought to embarrass or tarnish Masemola's reputation, insisting there was never any intention to portray him as complicit in fraud or corruption.

In this episode, we kick things off with a sobering snapshot of the freight industry's ongoing financial pain. Four companies are eliminating nearly 250 jobs at logistics and distribution facilities across New Jersey, North Carolina, Illinois, and California, while ⁠nine transportation and logistics-related companies have recently sought bankruptcy protection⁠. The largest announced workforce reduction involves Fusion Transport, a New Jersey logistics provider planning to lay off seventy-nine employees at its Piscataway facility effective October first, while bankruptcy filings continue to pile up across multiple freight segments. Next, we shift over to the agricultural freight sector, where a strategic acquisition is dramatically expanding access to specialized livestock hauling services. Springfield, Missouri-based BulkLoads announced Monday that it has ⁠acquired Livestock Network, an online load board and community serving the livestock transportation industry since 2000⁠. Livestock Network members will now gain access to BulkLoads' broader ecosystem of products, including Smart Freight Funding for freight factoring, Bulk Insurance Group, BulkTMS transportation management software, and Bulk Freight Insights market intelligence. Finally, we unpack a staggering shift in driver compensation as ⁠the Truck Driver Pay Index surged by 13.5 percent in just two months⁠. Jointly calculated by AscendTMS and Superior Trucking Payroll Services, the index hit 170.04 in June, up from 150.83 in April — easily the highest two-month gain in the history of the index, which has been calculated since 2020. With a typical lag of four to six months between higher spot rates and driver pay, experts suggest more increases are likely in the coming weeks and months. ⁠Follow the FreightWaves Today Podcast⁠ ⁠Other FreightWaves Shows⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we kick things off with a sobering snapshot of the freight industry's ongoing financial pain. Four companies are eliminating nearly 250 jobs at logistics and distribution facilities across New Jersey, North Carolina, Illinois, and California, while nine transportation and logistics-related companies have recently sought bankruptcy protection. The largest announced workforce reduction involves Fusion Transport, a New Jersey logistics provider planning to lay off seventy-nine employees at its Piscataway facility effective October first, while bankruptcy filings continue to pile up across multiple freight segments. Next, we shift over to the agricultural freight sector, where a strategic acquisition is dramatically expanding access to specialized livestock hauling services. Springfield, Missouri-based BulkLoads announced Monday that it has acquired Livestock Network, an online load board and community serving the livestock transportation industry since 2000. Livestock Network members will now gain access to BulkLoads' broader ecosystem of products, including Smart Freight Funding for freight factoring, Bulk Insurance Group, BulkTMS transportation management software, and Bulk Freight Insights market intelligence. Finally, we unpack a staggering shift in driver compensation as the Truck Driver Pay Index surged by 13.5 percent in just two months. Jointly calculated by AscendTMS and Superior Trucking Payroll Services, the index hit 170.04 in June, up from 150.83 in April — easily the highest two-month gain in the history of the index, which has been calculated since 2020. With a typical lag of four to six months between higher spot rates and driver pay, experts suggest more increases are likely in the coming weeks and months. Follow the FreightWaves Today Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

Our lead story: a public health emergency is declared in the Island Lakes region of northeastern Manitoba, as four First Nations jointly call on all levels of government to combat a health and housing crisis for their roughly 17,000 Ansininew citizens. >Interstitial: zapsplat.com

While meeting his Norwegian counterpart during the last leg of his four-nation tour in northern Europe, Chinese Foreign Minister Wang Yi told Espen Barth Eide that the two sides should elevate bilateral trade, and sign a China-Norway free trade agreement at an early date.

China and Finland have pledged to strengthen cooperation and coordination and to jointly address challenges. The announcement comes following a meeting between Finnish President Alexander Stubb and visiting Chinese Foreign Minister Wang Yi.

Chris’s Summary Jim and I continue our discussion on annuity insurer failures and state guarantee fund protections before turning to jointly owned annuities, examining how they differ from other jointly titled assets. We cover credited versus uncredited interest, mortality table calculations for annuitized contracts, and how a jointly owned annuity’s death benefit passes to named beneficiaries rather than the surviving owner. Contract language varies by insurer on how the surviving joint owner is treated relative to named beneficiaries. Jim’s “Pithy” Summary Chris and I pick up where we left off last week and close out our take on that NBC article about a woman whose annuity insurer ran into serious financial trouble. I get into the timing behind a related lawsuit, why I think the agent involved should have caught the warning signs, and why the insurance company itself deserves plenty of blame too. We also break down how state guarantee funds actually work once an insurer goes under, the difference between credited and uncredited interest, and what changes once you’ve annuitized and the fund has to figure out your payments using its own mortality tables. Then we shift into jointly owned annuities, and this is the part worth paying close attention to. Most people assume a joint annuity behaves like any other jointly titled asset, where the survivor automatically ends up owning the whole thing. However, that is not always how it works. I walk through language from two different insurance contracts we have dealt with over the years, and the two companies handle a joint owner’s death in completely different ways. If you have an older jointly owned annuity with someone other than your spouse listed as primary beneficiary, this is worth looking into now, because what actually happens at the first owner’s death might not be what you expect. The post What to Know About Jointly Owned Annuities: EDU #2626 appeared first on The Retirement and IRA Show.

Japan's three megabank lenders have announced plans to jointly issue a stablecoin, a type of digital asset, linked to currencies such as the yen and the U.S. dollar, during the year ending next March.

The Chinese Ministry of Public Security says it has worked with the US Drug Enforcement Administration under the Department of Justice on a joint investigation into a transnational case involving new psychoactive substances.

This accredited continuing education program is supported by an educational grant from Blueprint Medicine. It provides timely and practical education on systemic mastocytosis (SM). To obtain CME credit, visit https://checkrare.com/learning/p-systemic-mastocytosis-recognition-diagnosis-and-clinical-management/SM is a rare, chronic disorder driven by aberrant mast cell accumulation across multiple organ systems. Although diagnostic criteria are well established, a recent natural history study found that the average time to diagnosis is nearly five years. This prolonged delay—largely due to limited awareness of SM and its early symptoms—often results in unnecessary disease progression and inappropriate treatment. To address this clinical gap, this activity, led by Daniel J. DeAngelo, MD, PhD, Chief, Division of Leukemia at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston, MA, provides an overview of the early signs and symptoms of SM, outlines the appropriate diagnostic criteria and tools, and reinforces the importance of timely referral and testing for these patients to be properly managed. Led by a clinical expert with experience diagnosing and treating patients with SM, this 45-minute CME program will highlight early signs of SM, outline diagnostic criteria and tools, and reinforce the importance of timely referral/testing. Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hematology, dermatology, gastroenterology, immunology, and family practice. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of systemic mastocytosis and its clinical relevance.Apply best practices to diagnose systemic mastocytosis more efficiently.FacultyDaniel J. DeAngelo, MD, PhDChief, Division of LeukemiaDana-Farber Cancer Institute,Harvard Medical SchoolBoston, MADisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. DeAngelo discloses the following relevant financial relationships with ineligible companies:Consultant: Amgen, Autolos, Blueprint Medicines, Incyte, Jazz, Novartis, Pfizer, and Takeda Research Support: AbbVie, Glycomimetics, Novartis, and Blueprint MedicinesData Safety Monitoring Board: Daiichi-SankyoOther Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2026. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Japan's Sony Group Corp. said Friday that it has reached a basic agreement with Taiwan Semiconductor Manufacturing Co., the world's largest chip foundry, to form a strategic partnership for the joint development and production of next-generation image sensors.

This panel from the Realty Hack Summit cuts through the noise. Industry operators break down exactly how AI is being deployed inside real estate companies right now — from marketing and content creation to compliance, transaction management, and workflow automation. Moderated by Kelea Youngblood of Unlock MLS, the panel features Jay Tsao of Pivo Inc, Ryan Rodenbeck, CEO of Spyglass Realty, and Devin Dvorak, CEO of Jointly. The conversation covers practical AI tools agents can start using this week, how to avoid the trap of chasing every shiny new tool, and where human expertise still beats automation. They also get into how search is shifting from traditional SEO to AI-driven discovery, why authentic video matters more than ever in an AI-saturated internet, and what agents should be preparing for over the next 12 to 18 months. This is one of several full-length panels from the Realty Hack Summit, where top operators share what's actually working in real estate, AI, video marketing, and business systems.  

thecreativemastermind.com/ danielcubillo.tv@gmail.com ABOUT DANIEL Creating innovative, engaging audiovisual content for people, organizations, and causes telling stories that matter. I'm a showrunner, writer, and creative executive with over 30 years of experience, also working on independent creative projects and offering consulting services to the next generation of content creators. MEET DANIEL I have dedicated my life to content creation of all sorts. You name it: music video clips, wedding videos, live Real Madrid soccer games, awards galas, Real Housewives' episodes, interactive gameshows, influencer YouTube videos, historical TV movies, and beyond. I've spent decades identifying, developing, adapting, and producing audiovisual content, both for major players in the industry and for my own boutique production company. I've been lucky enough to learn from television legends, coworkers, mentors, bosses, peers, and teachers. Thanks to their generosity, wisdom, and expertise, I've accomplished incredible things, like creating and running a multimillion-euro primetime scripted drama and adapting and running from Los Angeles what became the most viewed show in Facebook Watch history at the time. Now, I'm excited to pass on that expertise to the next generation of content creators. I offer full-service consulting, mentorship, and production services to content creators, gamers, influencers, and other public figures who need hands-on support and guidance to get their unique story out there. I'm also constantly creating work of my own. I'm currently looking for the right partners to package my original content. Explore my project catalog here – for more information, contact me! MY CAREER: A LOVE STORY As a storyteller first and foremost, I think of my career as a full-blown epic saga, a four-act drama, a love story with all the highs and lows that come with it. Act One had me swooning hard. There's nothing quite like young love, and I first fell in love with content creation in my early teens, when my father taught me how to shoot and edit video during summer vacation. When that love was combined with my love of skiing and traveling, the chemistry was electric. It yielded a pilot for a travel show that didn't just fly, it soared, landing five seasons on Nat Geo and Grupo Planeta. I went from a solo act cutting clips in my living room to a full-blown production force. Act Two, I committed. Jumping from cable's charm to broadcast glitz, I found myself in the big leagues, with millions of eyes on the prize each night. Top Chef, Fear Factor, The Voice, Big Brother… I was showrunning with the best and learning about the game's cutthroat complexity. This was when I committed my life and soul to the art of storytelling. Act Three started out as my honeymoon phase. I ran the show… then ran the showrunners. From inception to air, I juggled development departments and the high-stakes sales market. The exec life chose me, and I embraced it. But as much as I learned, as much as I soared, I also felt distanced from my true love. I saw firsthand how the essence of storytelling often gets sidelined by the top brass. And that sting? It felt a lot like heartbreak. Act Four is where I find myself now: the rekindling. I'm back to my roots, to the content that beats true to my heart, not just what the market dictates. And every new voice I mentor reignites my passion and makes me feel committed and passioned again. Jointly, we're rewriting the script, elevating narratives, and crafting content that doesn't just fit the bill, it sets the bar. MY BOOK A strategic field guide for creators, storytellers, and entertainment professionals navigating the new content-driven world. BUY NOW *Avaliable in Hardcover, Paperback, eBook & AudioBook.

Senior Chinese diplomat Wang Yi has urged China and France to help stabilize a turbulent world, stressing China-EU partnership and dialogue, as France reaffirmed its commitment to working with Beijing on global challenges.

Jerusalem Church Leaders Jointly Condemn Christian Zionism

Thursday marked the opening of an institution of learning that aims to upskill over 100,000 delivery workers. China's first "rider academy" was launched in Guangdong province, in a move that reflects the authorities' push to support the expanding courier workforce.周四，一个旨在提升10万余名配送员技能的教育机构正式揭牌。中国首家“骑手学院”在广东成立，体现出政府对不断壮大的快递与配送群体的支持力度。Jointly established by the Guangdong provincial education authority and e-commerce giant JD, the Modern Grassroots Workers Academy, widely referred to as the "rider academy", was inaugurated at Guangzhou Polytechnic University, marking China's first dedicated vocational education platform for full-time delivery personnel.由广东省教育部门与电商巨头京东联合共建的“现代基层劳动者学院”（广称为“骑手学院”）在广州科技职业技术大学揭牌，成为国内首个面向专职配送人员的职业教育平台。Lin Rupeng, director of the Guangdong Department of Education, said the academy reflects Guangdong's push to link education and talent chains more closely with the province's industrial and innovation needs, while building stronger safeguards for workers in emerging forms of employment and empowering them for future changes in the job market.广东省教育厅厅长林如鹏表示，学院体现了广东将教育链、人才链与产业链、创新链深度融合的努力，同时为新就业形态劳动者提供更完善保障，帮助其适应未来就业市场变化。"Through the enabling power of education, we are opening a new pathway for the career development of delivery riders, and by bringing universities and enterprises together, we are creating a more dynamic model of industry-education integration," he said.他说：“通过教育赋能，我们为外卖骑手开辟职业发展新通道；通过高校与企业协同，我们正在打造更加活跃的产教融合模式。”According to Feng Lei, a senior executive with JD, the academy will rely on university facilities, training centers and teaching staff across Guangdong, with Guangzhou Polytechnic University serving as the core base and several other colleges running satellite training points. Over the next three years, it will train more than 100,000 full-time riders and frontline couriers whom JD employs in the province.京东高管冯蕾介绍称，学院将依托广东多所高校的设施、培训中心和师资力量，以广州科技职业技术大学为核心基地，并在多所院校设置培训点。未来三年，学院将在广东培训超过10万名京东全职骑手与一线配送员工。The curriculum is designed to be practical and closely aligned with industry needs and development. Riders will access courses including food safety, mental well-being and English. To prepare for emerging delivery technologies, a training base for drone operators and related high-tech roles will be established, and qualified riders could be channeled into positions such as warehouse supervisors or drone pilots.课程设计强调实用性，与行业需求高度契合。骑手将学习食品安全、心理健康、英语等课程。为应对配送科技发展，学院还将建设无人机操作等高技术岗位的培训基地，合格学员将有机会转岗为仓储主管或无人机驾驶员。Guo Shuzhao, a JD rider, said the courses are closely aligned with their day-to-day work, covering not only operational skills but also safety regulations and service standards.京东骑手郭树钊表示，课程内容与日常工作高度相关，不仅涵盖操作技能，还包括安全规范和服务标准。"By completing the training to get certificates, our opportunities for career advancement will increase significantly," he said.他说：“完成培训并取得证书后，我们的晋升机会会明显增加。”The initiative comes as delivery riders, couriers, online shop owners, livestream sellers and ride-hailing drivers, classified in China as new forms of employment, become increasingly central to urban life. There are already 84 million workers nationwide engaged in such employment, data from the All-China Federation of Trade Unions showed.该举措出台之际，随着外卖骑手、快递员、网店经营者、直播带货者、网约车司机等新就业形态劳动者在城市生活中日益重要，全国已有8400万劳动者从事相关工作（全国总工会数据）。The size of this workforce and the volatility it faces have prompted several provinces to introduce structured training programs. Jiangsu launched a three-year action plan in October to expand skills training for people in these new forms of employment, covering smart-device use, labor rights and e-commerce entrepreneurship.由于这一庞大群体面临就业波动，多地已出台系统培训计划。例如江苏省今年10月启动三年行动方案，涵盖智能设备使用、劳动权益、电子商务创业等内容。The launch of the rider academy also comes amid rapid advances in automated delivery. Companies such as Meituan have expanded drone routes in major cities like Shenzhen in Guangdong, while completing more than 520,000 orders nationwide by early 2025, data from Meituan showed.骑手学院的成立，也正值自动化配送迅速发展之际。美团等企业已在深圳等城市扩大无人机配送航线，截至2025年初已完成52万余单（美团数据）。While drones and robots may reduce labor costs, Feng Lei from JD said that drones and related delivery equipment and technologies will not completely substitute for delivery personnel.尽管无人机和机器人有助于降低成本，但冯蕾表示，它们不会完全取代配送人员。She said emerging technologies "raise the skill requirements rather than eliminate the need for riders". Delivery personnel increasingly need to operate intelligent order systems and collaborate with drones and robots to complete deliveries, she said.她指出，新技术“提升了岗位技能要求，而非消灭岗位本身”。骑手未来需要操作智能派单系统，并与无人机、机器人协同完成配送。Feng Lipan, an e-commerce associate professor at South China University of Technology in Guangzhou, said the new academy is precisely intended to prepare riders for that transition.华南理工大学电子商务系副教授冯立攀表示，新学院正是为骑手应对这一转型而设。"It will reshape the public's stereotypical perception of the delivery rider profession, transforming it into a skilled occupation recognized for both mental agility and technical expertise," he said.他说：“这将重塑公众对配送职业的刻板印象，使其成为兼具思维敏捷与技术能力的技能型岗位。”industry-education integration产教融合emerging forms of employment新就业形态automated delivery自动化配送workforce volatility就业波动

Chinese President Xi Jinping holds an informal meeting with his French counterpart in southwest China, saying the two countries should jointly contribute to global peace and stability through dialogue and cooperation (01:13). Japanese protesters are again urging the prime minister to retract her remarks on China's Taiwan region and resign (15:18). Russian President Vladimir Putin is on his first state visit to India in four years (25:40).

Once again, Bad Bunny is dominating music headlines and social media as his brand-new “Debí Tirar Más Fotos World Tour” launched with a pair of sold-out shows at Estadio Olímpico Félix Sánchez in Santo Domingo on November 21 and 22. According to a vivid recap from DropVibe, the kickoff event was electric, cementing Bad Bunny's reputation for turning concerts into full-blown cinematic experiences. The final act erupted with fireworks and confetti, fans singing along to every word, capturing the fusion of spectacle, community, and personal connection that defines his current era.Americanonewspaper.com reports that fans lined up hours before the gates opened and remained outside well into the concert amid access snafus—underscoring the feverish demand for tickets on this tour. Bad Bunny performed fan favorites like “Callaita,” “Baile Inolvidable,” “Tití Me Preguntó,” and “Yo Perreo Sola,” but also treated Dominican Republic listeners to exclusives including “25/8” and a collaborative performance with local dembow legend El Alfa. His setlist wove together tributes to Puerto Rico, emotional storytelling, and commentary on Caribbean life, reflecting the deeper, nostalgic tone of his upcoming album, also titled Debí Tirar Más Fotos.According to TheLagosReview and NME, that sixth studio album is officially set for release on January 5, 2026. Bad Bunny previewed the album's reflective spirit—centered on the importance of memory, photographs, and living in the present—in a video teaser featuring Puerto Rican filmmaker Jacobo Morales. Fans are also already spinning his new holiday single “Pitorro de Coco,” which infuses heartbreak into festive season traditions and showcases his range as both a vocalist and storyteller.LaMezcla.com confirms the world tour is set to take him across Latin America, Australia, and Europe well into next summer, with a historic nine-show run slated in Mexico City and performances in major cities from Sydney to Buenos Aires. Jointly, the tour marks yet another high in Bad Bunny's trajectory, building on streaming records and sold-out arenas: Billboard recently hailed him as the top Latin artist of the 21st century and Spotify's most-streamed Latin artist in 2024.Adding to the current media frenzy, The Guilfordian and StingerEHS report that Bad Bunny's cultural reach is about to take center stage in the U.S. as he has been tapped to perform at Super Bowl LX, sending waves across social media as fans react to the news and speculate about potential surprise guests or genre fusions.His popularity is so influential that Yale University is keeping its course dedicated to his music and impact, with CT Public noting that his ascent—from streaming icon to halftime headliner—continues to shape cultural conversations on and off campus.On Instagram and TikTok, excerpts from the Santo Domingo concerts, behind-the-scenes moments, and snippets of his newest tracks have racked up millions of views. Fans are dissecting the album teaser's themes and his interactions with Dominican fans, where he expressed heartfelt gratitude and called the Dominican Republic his second home. As tour dates continue to sell out and excitement for the album peaks, it's clear Bad Bunny remains not just a songwriter and performer, but a global cultural phenomenon whose every move sets trends and sparks conversation.Thanks for tuning in—be sure to come back next week for more updates on Bad Bunny and all things music, culture, and entertainment. This has been a Quiet Please production; for more, check out QuietPlease.ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

This accredited continuing education program is supported by an educational grant from Sanofi. Credit for the program can be obtained by visiting https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-cidp/ . This program, led by Jeffrey Allen, MD, Professor of Neurology at the University of Minnesota provides an overview on the diagnostic delays that often occur in patients with CIDP as well as best practices to suspect and diagnose this rare condition more efficiently. This activity has been designed to meet the educational needs of physicians specializing in family medicine, pediatrics, and neurology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of CIDP.List best practices which can be used to diagnose CIDP more efficiently.Faculty Jeffrey Allen, MDProfessor of NeurologyDepartment of NeurologyDivision of Neuromuscular MedicineUniversity of MinnesotaMinneapolis, MNDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses Consultant/Educational talks: Annexon, Alexion, Amgen, CSL Behring, Takeda,BioCryst, Grifols, Argenx, Sanofi, Immunovant, ImmunoAbs, Octapharma, Alnylam, AstraZeneca, Dianthus, Johnson & Johnson, Laboratoire Français du Fractionnement et des Biotechnologies, Nuvig, Akcea Therapeutics, ImmunoPharma,Pfizer.Community Faculty/Patient (Christine Eleeson): No relevant financial relationships with any ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre-and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Welcome to Calvary Lutheran Church 619 3RD AVE SW, PERHAM, MN 56573 Thank God. Share Jesus. Help Others Prayer of the Day Almighty God, you have knit your people together in one communion in the mystical body of your Son, Jesus Christ our Lord. Grant us grace to follow your blessed saints in lives of faith and commitment, and to know the inexpressible joys you have prepared for those who love you, through Jesus Christ, our Savior and Lord, who lives and reigns with you and the Holy Spirit, one God, now and forever. Amen.   Support Our Livestream Ministry—and Empower Our Youth! Each week, our YouTube, Facebook Live and our podcast services are made possible by our amazing youth media team. That's right—they run the cameras, audio, and streaming software—and we're proud to pay them for their work, helping them build life skills while serving the church. Your donation supports: Livestream costs (equipment, internet, tools) Paid media roles for our youth Continued outreach through digital ministry If you've been blessed by our services, consider giving here: https://www.calvaryperham.com/gifts Thank you for helping us serve our community—and raise up the next generation! Facebook: / calvaryperham YouTube: / @calvaryperham Podcast on Spotify https://open.spotify.com/show/7hbXujm... Podcast public site https://rss.com/podcasts/april16th2023/ Lakes 99.5 Radio Sundays at Ten Thirty AM https://player.listenlive.co/64121 TUESDAY WORSHIP 9 AM Arvig TV Channel 14 Egiving https://secure.myvanco.com/YMVS/home Website: https://calvaryperham.com/ Vanco Mobile App on Phone/Tablet: Vanco Mobile Faith Engagement has replaced the Give+ App. Search “vanco mobile faith engagement” in the app store to download on your phone or tablet, Calvary is “Calvary Lutheran Church ELCA.” Website: Click the orange E-Giving button at https://calvaryperham.com/

In his speech at the second session of the 32nd APEC Economic Leaders' Meeting, Chinese President Xi Jinping has called on Asia-Pacific economies to strengthen cooperation and create a sustainable and prosperous future.

In a landmark moment for education and cross-border cooperation, the first-ever all-island apprenticeship programme has been launched, marking a new chapter in how Ireland and Northern Ireland develop talent for the future. The Accounting Technologist Apprenticeship, developed by ATI and delivered jointly by Technological University of the Shannon and The Open University in Northern Ireland, will equip learners with cutting-edge skills in digital finance and sustainability, responding to the evolving demands of the sector. Taoiseach Micheál Martin, Tánaiste Simon Harris, Minister for Further and Higher Education, Research, Innovation and Science James Lawless TD, Minister for the Economy in Northern Ireland Dr Caoimhe Archibald, Minister of State Marian Harkin, and Gillian Doherty, COO of ATI, today officially launched the programme. Developed by ATI, the Certified Accounting Technologist's new role bridges the gap between the traditional Accounting Technician and a fully qualified accountant. The apprenticeship was created in response to the disruptive impact of AI and emerging sustainability reporting requirements. Learners will gain the skills needed to support finance teams in transitioning to digital and sustainable economic models, positioning them to add strategic value in a rapidly evolving sector. Taoiseach Micheál Martin said, "The launch of the new all-island Accounting Technologist Apprenticeship is a landmark in our shared approach to skills, opportunity and economic development. It reflects our commitment to working together across this island to prepare people for the future economy and to ensure that talent and innovation can thrive in every community. This apprenticeship is a strong example of what we can achieve through practical cooperation and shared ambition." Tánaiste Simon Harris added, "By investing in apprenticeships like this, we are showing that opportunity should know no borders and that talent can be nurtured through many different pathways. This all-island programme is a powerful example of what we can achieve through partnership, innovation and a shared commitment to preparing people for the future world of work. The Certified Accounting Technologist is an entirely new occupation, and Ireland is excited for the opportunities that it will create." Minister Lawless said: "The launch of the first apprenticeship delivered in both Ireland and Northern Ireland is a landmark achievement in our shared ambition to build a future-ready workforce across the island. It strengthens economic cooperation and competitiveness on a North-South basis and reflects the kind of practical collaboration that drives long-term prosperity. "In today's global knowledge economy, talent and ideas are our most valuable resources, and our people are our greatest natural asset. The Certified Accounting Technologist will play a vital role in linking traditional accounting and corporate reporting with cutting-edge areas such as sustainability, AI and analytics, equipping learners with the skills to lead in a rapidly evolving sector. "This is more than an apprenticeship. It is a blueprint for how we grow talent, foster innovation, and shape the future of work on an all-island basis. "I commend all partners for their vision and collaboration in delivering an apprenticeship that embodies innovation, inclusion and strategic foresight. I look forward to seeing this programme as a foundation for deeper cooperation on skills and talent development across our island." Minister Archibald said: "I am committed to expanding apprenticeship opportunities across the island, fostering cross-border collaboration and shared growth. "The new All-Island Accounting Technologist Apprenticeship is a major step forward. It enhances our curriculum and prepares learners for the evolving demands of the accounting profession. "This programme directly addresses the rise of artificial intelligence and the growing need for sustainability reporting - skills ...

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

With book bans in public schools rising to levels unseen since the McCarthy era Red Scare of the 1950s, the Eleanor Roosevelt Banned Book Awards ceremony at the Bardavon in Poughkeepsie, N.Y. will be presented jointly with PEN America on Saturday, October 11th. Author Jennifer Finney Boylan, PEN America's president, will be the keynote speaker.Ten honorees include best-selling author Margaret Atwood (The Handmaid's Tale), who will receive the Eleanor Roosevelt Lifetime Achievement Award at the Bardavon in Poughkeepsie on October 11th.

The Midwest Regional Broadcasters Clinic is where broadcast engineers and technologists gather each year to learn, share, and connect. Hosted in Wisconsin, this premier event features deep-dive sessions on both cutting-edge and legacy technologies, a vibrant trade show floor, and plenty of opportunities to network with peers from across the Midwest and beyond. Jointly organized by the Wisconsin and Minnesota Broadcasters Associations along with SBE chapters from both states, it’s a true collaboration for the industry. This year, TWiRT is once again going live from the trade show floor—right in the middle of the action—bringing you the latest insights, innovations, and conversations from one of the broadcast community’s most valuable gatherings. Guests:Jim Armstrong - Senior Director of Sales US/Canada at Telos AllianceWilliam Kerkhof - Director of Engineering RTVF at University of Wisconsin Oshkosh Paul Kriegler - US Manager Omnia Sales at Telos AlliancePaul Stewart - President at Summit Technology GroupBrad Young - Sales Manager at WideOrbit Keith Paglia - Sales and Marketing at Sprite Media, Inc.Seth Stevenson - Broadcast Engineer Intern at Northwestern MediaEarl Sondreal - Director of Sales & Marketing, Americas at InovonicsBob Goff - General Manager at Heart of Wisconsin Media LLC Host:Kirk Harnack, The Telos Alliance, Delta Radio, Star94.3, South Seas, & Akamai BroadcastingFollow TWiRT on Twitter and on Facebook - and see all the videos on YouTube.TWiRT is brought to you by:Broadcasters General Store, with outstanding service, saving, and support. Online at BGS.cc. Broadcast Bionics - making radio smarter with Bionic Studio, visual radio, and social media tools at Bionic.radio.Aiir, providing PlayoutONE radio automation, and other advanced solutions for audience engagement.Angry Audio and the new Rave analog audio mixing console. The new MaxxKonnect Broadcast U.192 MPX USB Soundcard - The first purpose-built broadcast-quality USB sound card with native MPX output. Subscribe to Audio:iTunesRSSStitcherTuneInSubscribe to Video:iTunesRSSYouTube

The Midwest Regional Broadcasters Clinic is where broadcast engineers and technologists gather each year to learn, share, and connect. Hosted in Wisconsin, this premier event features deep-dive sessions on both cutting-edge and legacy technologies, a vibrant trade show floor, and plenty of opportunities to network with peers from across the Midwest and beyond. Jointly organized by the Wisconsin and Minnesota Broadcasters Associations along with SBE chapters from both states, it's a true collaboration for the industry. This year, TWiRT is once again going live from the trade show floor—right in the middle of the action—bringing you the latest insights, innovations, and conversations from one of the broadcast community's most valuable gatherings.

The accredited CME program highlights the latest clinical research about hemophilia, a rare, genetic bleeding disorder. Led by Dr. Steven Pipe, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. This program is supported by an educational grant from Sanofi.To receive CME credit, visit https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hemophilia. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with hemophilia and its clinical relevance.Steven Pipe, MDProfessor of Medicine,University of Michigan Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Pipe discloses the following relevant financial relationships with ineligible companies:Consultant: Bayer, BioMarin, CSL Behring, Hema Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Roche/Genentech, Sanofi, Takeda, Spark TherapeuticsScientific Advisory Committee: GeneVentiv, Equilibra BioscienceGrant/Research Support: Siemens, YewSaving Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about iTTP, a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in iTTP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with iTTP and its clinical relevance. Shruti Chaturvedi, MDAssistant Professor of MedicineJohns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This accredited CME program highlights the latest clinical research about immune thrombocytopenia (ITP), a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this program provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in ITP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with ITP and its clinical relevance.FacultyShruti Chaturvedi, MDAssistant Professor of Medicine,Johns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This program is supported by an educational grant from UCB, Inc. This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.  This program, led by Dr. James Howard Jr, provides a summary of clinically relevant data presented at the American Academy of Neurology Annual Meeting (AAN 2025) held in San Diego, CA that can enhance the care of patients with myasthenia gravis.  To obtain CME credit for this program, visit https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-aan-2025/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology, rheumatology, and family practice. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with myasthenia gravis and its clinical relevance.FACULTY James F. Howard Jr, MD, FAANProfessor of NeurologyUniversity of North Carolina at Chapel HillDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Howard discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Cartesian Therapeutics, CoreEvitas, Curie.bio, Hansa Biopharma, H. Lundbeck A/S, Merck EMD Serono, NMD Pharma, Novartis Pharma, Regeneron Pharmaceuticals, Sanofi US, Seismic Therapeutics, TG Therapeutics, Toleranzia AB, and UCB PharmaGrant/Research Support: Ad Scientiam, Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, NMD Pharma, and UCB PharmaOther Relationships: non-financial support (eg travel) Alexion AstraZeneca Rare Disease, argenx, Biohaven Ltd, Cartesian Therapeutics, Toleranzia AB, and UCB Pharma.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.CREDIT Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

In this eye-opening episode of Don't Go Broke Trying, Reni sits down with Aimee Schalles and Amanda Baron, two practicing lawyers and co-founders of Jointly, a legal tech platform making prenups and cohabitation agreements more accessible for everyday Canadians.Together, they unpack the stigma around prenups and explain why legal agreements like prenups, postnups, and cohabitation contracts are important tools for anyone in a serious relationship, not just for celebrities and millionaires.From breaking down what these agreements really mean, to busting the myths that make people avoid them, this conversation will make you rethink what financial protection in love actually looks like.What You'll Learn in This Episode:The difference between prenups, postnups, and cohabitation agreementsWhy everyone, not just wealthy couples should consider oneHow to bring up a prenup with your partner (without killing the romance)What a prenup can and can't include (especially when it comes to kids, houses, and businesses)How to use these agreements as tools of care, not conflictThis episode will leave you with a clear understanding of what prenups are (and aren't), why they're not just for the rich and famous, and how they can actually strengthen your relationship not weaken it.Resources Mentioned: Learn more about Jointly: https://getjointly.ca/Prenup legal course by Jointly: https://getjointly.ca/learning-center/Follow Jointly: https://www.instagram.com/getjointly/Watch on Youtube: https://youtu.be/EqUhVt7hOws?si=QrW5eM6iRqF-83eQ Connect With My Guests:Aimee - https://www.linkedin.com/in/aimeeschalles/Amanda - https://www.linkedin.com/in/amandabaron/Join Don't Go Broke Collective: ⁠https://www.skool.com/dont-go-broke-collective/aboutConnect With Us!Follow the podcast on Instagram: ⁠⁠⁠https://instagram.com/dontgobroketrying Follow Reni on Instagram: ⁠⁠⁠https://www.instagram.com/xoreni Visit our website: ⁠⁠⁠⁠renitheresource.com/category/podcast⁠⁠⁠⁠Follow on Twitter: ⁠⁠⁠⁠twitter.com/dgbtpod⁠⁠⁠⁠Subscribe to Reni's YouTube: https://youtube.com/xoreniDISCLAIMER: The views and opinions shared on this channel are for informational and educational purposes only. This is NOT financial advice. Always do your own research and due diligence before investing.

AP correspondent Charles de Ledesma reports Ukraine is forging ahead with embryonic plans for joint weapons production with some of its international allies, as U.S. says it is halting some arms shipmentsfor Kyiv.

Send us a textJoin us as we sit down with Enrolled Agent, and Founder of Golden Lion Tax Solutions, Morgan Q. Anderson, to discuss everything you need to know about Innocent Spouse Protection and Relief when filing jointly on an income tax return.As a leading divorce firm in Portland, our attorneys provide guidance on custody, alimony, separation, estate planning, and more. Learn what to expect in Oregon and Washington divorce cases and how we can help.If you would like to speak with one of our attorneys, please call our office at (503) 227-0200, or visit our website at https://www.pacificcascadelegal.com.To learn more about Morgan and how she can help you with your tax questions, you can visit her website at: https://www.goldenliontaxsolutions.com/Disclaimer: Nothing in this communication is intended to provide legal advice nor does it constitute a client-attorney relationship, therefore you should not interpret the contents as such.